Skip to main content
Publications
Johannes CB , Beachler DC, Layton JB , Danysh HE , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE , Johannes CB , Beachler DC, Layton JB , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Forns J , Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C . Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study . Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y
Gilsenan AW , Sturkenboom MC, De Luise C, Cohet C, Anderson SA, Brown J, Foskett N, Perez-Gutthann S . COVID-19 vaccine safety monitoring: opportunities, challenges and lessons learned for pharmacoepidemiology . Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark.
Fuller CC, Kawai AT , Haynes K, Coughlin K, Reynolds JS, Hawrusik R, Horgan C, Calingaert B , Johannes CB , Bradley Layton J , Peterson A, Praet N, Willame C, Yost E, Brannan C, McMahill-Walraven CNN, Guzman M, Jamal-allial A, Nair V, Seals RM, Wang FT, Selvan M, Ma Q, Platt R, Gilsenan AW , Brown J. Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study . Presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Johannes C , Layton JB , Beachler DM, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of acute kidney injury in real-world use of dapagliflozin . Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Johannes C , Layton JB , Beachler DC, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of severe complications of urinary tract infection in real-world use of dapagliflozin . Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Forns J , Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Reutfors J, Rebordosa C . Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments . Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Danysh HE , Gilsenan A , Beachler DC, Kaye JA , Garcia-Albeniz X , Schmid R, Hunter S, Hunt PR, Aguado J , Calingaert B , Layton JB , Gutierrez L . Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Layton JB , Zhou CK, Danysh HE , Bleachler DC, Ziemiecki R , Dinah J, Yin R, Calingaert B , Hunt PR, Gilsenan AW , Johannes CW . Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA , Pladevall-Vila M , Garcia de Albeniz X , Hunt PR, Gilsenan A , Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE , Layton B , Beachler DC, Arana A , Pladevall-Vila M , Schmid R, Calingaert B , Ziemiecki R , Hunt PR, Gilsenan A , Johannes C . Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Rebordosa C , Houben E, Laugesen K, Bothner U, Montonen J, Aguado J , Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW . No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study . Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study . Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J , Gilsenan A , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350 . Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA , Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study . Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Rebordosa C , Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J , Overbeek J, Ehrenstein V, Wallace L, Gilsenan A . Utilization of olodaterol and indacaterol in Europe . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864
Fortuny J , Gilsenan AW , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J , Flynn RW, Plana E , Ziemiecki R , Andrews EB, Gilsenan A . Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Harris D , Casso D, Midkiff K , Anderson A, Gilsenan A , Oliveria A, Andrews E, Kellier-Steele N. Methods, results, and lessons learned from two postmarketing drug safety surveillance studies linking state cancer registry data to large pharmacy databases . Presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Millar M, Kinney AY, Camp N, Cannon-Albright L, Hashibe M, Penson D, Kirchhoff A, Neklason D, Gilsenan A , Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 population-based studies . Am J Epidemiol. 2019 May 1;188(5):928-39. doi: 10.1093/aje/kwz011